Genoskin Launches ISR Platform, the First Human Skin Ex Vivo Platform to Study Injection Site Reactions (ISR)

– New patent filed protecting Genoskin’s unique ISR platform®, enabling human testing of allergic or pseudo-allergic inflammatory reactions induced by injectable drugs – Validation of the ISR platform® achieved with partner Catalyst Biosciences, early adopter of the platform, to identify lower ISR risk formulation – Unique offer aims to disrupt drug development by enabling first-in-human data generation ahead of clinical trials Genoskin, a biotechnology company that provides transformative platforms and tools leveraging human skin to test therapeutic and non-therapeutic products, today announces the launch of its ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans, ahead …

Read the source article at sofw.com
2021-07-21 10:25:00